Breaking News

Lonza to Expand HPAPI Development and Manufacturing Capacity

Will develop new facilities at Visp site; enters long term mfg. agreement with AstraZeneca

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lonza, a contract development and manufacturing organization (CDMO) partner to the biopharma industry, has unveiled an investment in a major expansion of highly potent API (HPAPI) capacity at its Visp, Switzerland site to meet increased market demand.   The investment will add two 4m3-scale, multi-purpose production lines for HPAPI manufacturing complementing Lonza’s existing range of production capacities from lab to large commercial scale. A subsequent capacity optimization will also improve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters